Fig 1: miR-672-5p Treatment Mitigates Ovariectomy-Induced Sarcopenia(A) Body weight, (B) lean mass, and (C) serum CK levels. Data are mean ± SE. *p < 0.05 and **p < 0.01 compared with the PBS-treated group, or as shown ˆp < 0.05, ˆˆp < 0.01, and ˆˆˆp < 0.001 (n = 6 mice per group). (D) Representative photomicrographs of H&E-stained sections of gastrocnemius muscle from the indicated groups (n = 3, magnification 40×). (E) Cross-sectional area (CSA) and (F) Feret’s diameter. Data are mean ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the PBS-treated group, or as shown ˆˆˆp < 0.001. (G and H) Immunostaining for laminin (G) and immunostaining for Atrogin-1 (H) (n = 3, magnification 40×). mRNA expression (qPCR, in triplicate) of MyoD (I), Atrogin-1 (J), and MuRF-1 (K) and protein expression (L) (western blotting) of muscle differentiation marker; MyoD (MA1-41017-Thermo Scientific; 1:1,000), catabolic markers, atrogin-1 (ab74023-Abcam; 1:1,000), and muscle ring-finger protein-1 (MuRF-1, ab183094-Abcam; 1:1,000) from gastrocnemius muscles of indicated groups. ß-actin (sc-47778 Santa Cruz Biotechnology; 1:500) was taken as a loading control. Secondary antibodies (either anti-rabbit or anti-mouse; 1:10,000) were HRP conjugated (Sigma-Aldrich). Data are mean ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the PBS-treated group.
Supplier Page from Abcam for Anti-Fbx32 antibody